Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused...
27 KB (2,911 words) - 15:37, 21 August 2024
measures for RSV disease remain limited to good hygiene and the use of palivizumab, a monoclonal antibody used only for high-risk children, including premature...
102 KB (10,220 words) - 14:17, 8 October 2024
inhibitor, and has shown good results in Phase II and III clinical trials. Palivizumab Presatovir Lumicitabine Zheng X, Gao L, Wang L, Liang C, Wang B, Liu...
3 KB (171 words) - 19:10, 25 January 2023
study showed that nirsevimab had a similar safety profile compared to palivizumab (Synagis). The US Food and Drug Administration (FDA) evaluated the safety...
24 KB (1,917 words) - 17:27, 12 October 2024
Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin Roxadustat...
10 KB (778 words) - 01:56, 27 September 2024
Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin Roxadustat...
79 KB (6,427 words) - 19:30, 7 October 2024
Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin Roxadustat...
91 KB (9,320 words) - 03:57, 2 October 2024
Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin Roxadustat...
16 KB (1,284 words) - 04:32, 23 September 2024
Passive antibody therapy (section Palivizumab)
large-cell lymphoma in 2011. In 1998, the FDA approved the medical use of palivizumab (trade name: Synagis), which is a humanized monoclonal antibody used...
27 KB (2,923 words) - 15:03, 4 April 2024
Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin Roxadustat...
42 KB (3,486 words) - 00:32, 30 September 2024